Reply Dutch government, received 2025-01-23

Questions by the member Van Meijeren (FVD) to the Prime Minister and the State Secretary for Health, Welfare and Sport on the letter from the NORTH group (sent 31 December 2024).

Reply by State Secretary Karremans (Health, Welfare and Sport) (received 17 January 2025).

Question 1

How do you assess the attached letter and scientific rationale from the NORTH group on the safety and efficacy of the modified mRNA products for COVID-19?[1]

Answer 1

Dutch vaccination policy is based on independent scientific advice. Reports on vaccines are continuously monitored and investigated. If necessary, appropriate action is taken to ensure the safety of vaccinations. In answering various written questions on COVID-19 vaccination, my predecessors have already extensively addressed in detail the concerns expressed in the said letter. Below, I have included references to these previous answers.

Question 2

Do you acknowledge that the injections against COVID-19 have never been tested for their ability to stop virus transmission? If not, why not? If yes, how do you the concerns expressed in the letter about this?

Answer 2

For a detailed explanation on this subject, I refer to the answers to written questions by Member Van Haga (Group Van Haga) dated 12 October 2022.[2]

Question 3

Do you acknowledge that COVID-19 injections resulted in an unprecedented number of reported adverse events, as well as deaths? If not, why not? If so, how do you assess the concerns expressed in the letter regarding this?

Answer 3

For a detailed explanation of the number of reported adverse events, I refer to the answer to written questions by member Van Haga dated 25 July 2022.[3] There is broad scientific consensus that the COVID-19 vaccines protect well against serious illness and death.

Question 4

Do you acknowledge that analyses by multiple, independent scientists indicate to variable and excessive amounts of residual plasmid DNA in the Pfizer and Moderna products, which should never have entered marketed vials? If no, why not? If yes, how do you assess the concerns expressed in the letter in this regard?

Answer 4

I do not subscribe to these analyses. For a detailed explanation, see the answers to written questions by Member Van Haga dated 17 April [4] and 3 October 2023[5]. I also refer to the response that the Australian Therapeutic Goods Administration (TGA) has given in response to messaging on this issue.[6]

Question 5

Are you prepared to immediately end the use of modified mRNA injections for COVID-19, as well as initiating a recall of these products? If not, why not?

Answer 5

No, see my answer to question 1.

Question 6

Are you prepared to conduct an independent and transparent investigation into the adherence to regulations, method of approval and use of the mRNA injections? If not, why not?

Answer 6

The safety of COVID-19 vaccines has been extensively researched and assessed by several independent scientific bodies, including the European Medicines Agency (EMA) and the Health Council. I see no reason to commission additional research into the method of approval and use of COVID-19 vaccines.

Question 7

Can you provide the Chamber with scientific evidence that the claim, that there is absolutely no risk of harm to human DNA, irrefutably substantiates? If not, why not?

Answer 7

Due to the absence of the right excipients (enzymes), both the mRNA and any bits of plasmid DNA that may have been left behind in the vaccine cannot enter the cell nucleus of the body cells where the DNA is located. Thus, vaccines cannot alter human DNA. For further explanation, I refer to the letter to your Chamber of 6 March 2023.[7]

---

[1] Annex enclosed
[2] ah-tk-20222023-978.pdf
[3] ah-tk-20212022-3796.pdf
[4] ah-tk-20222023-2862.pdf
[5] ah-tk-20232024-475.pdf
[6] Therapeutic Goods Administration(18 oktober 2024). «Addressing misinformation about excessive DNA in the mRNA vaccines». https://www.tga.gov.au/news/media-releases/ addressing-misinformation-about-excessive-dna-mrna-vaccines
[7] kst-25295-2032.pdf